{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "9935256",
  "DateCompleted": {
    "Year": "1999",
    "Month": "02",
    "Day": "17"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "06",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0002-9610",
      "JournalIssue": {
        "Volume": "176",
        "Issue": "6A Suppl",
        "PubDate": {
          "Year": "1998",
          "Month": "Dec"
        }
      },
      "Title": "American journal of surgery",
      "ISOAbbreviation": "Am J Surg"
    },
    "ArticleTitle": "Pharmacodynamics and microbiology of trovafloxacin in animal models of surgical infection.",
    "Pagination": {
      "StartPage": "39S",
      "EndPage": "45S",
      "MedlinePgn": "39S-45S"
    },
    "Abstract": {
      "AbstractText": [
        "Trovafloxacin provides broad in vitro and in vivo coverage of the aerobic and anaerobic pathogens found frequently in surgical infections. In vitro susceptibility testing indicated that trovafloxacin inhibited gram-positive staphylococci and enterococci, numerous gram-negative organisms, including Escherichia coli, and anaerobic pathogens, such as Bacteroides fragilis. Trovafloxacin protected mice from lethal infections induced by gram-negative or gram-positive organisms, even when these organisms were inoculated in combination with B. fragilis. Trovafloxacin protected rats in models of intra-abdominal sepsis induced by inoculation with E. coli and B. fragilis or with multiple aerobic and anaerobic pathogens. In these experimental models, trovafloxacin protected rats from lethal infection, reduced intra-abdominal abscess formation, and inhibited bacterial growth. Drug concentrations were greater in intra-abdominal abscesses than in serum, reflecting the good tissue penetration of trovafloxacin. These results indicate that trovafloxacin may be effective in prophylaxis and treatment of mixed infections in surgical patients."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA."
          }
        ],
        "LastName": "Onderdonk",
        "ForeName": "A B",
        "Initials": "AB"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Am J Surg",
    "NlmUniqueID": "0370473",
    "ISSNLinking": "0002-9610"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Fluoroquinolones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Naphthyridines"
    },
    {
      "RegistryNumber": "9F388J00UK",
      "NameOfSubstance": "trovafloxacin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "microbiology",
        "prevention & control"
      ],
      "DescriptorName": "Abdominal Abscess"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "pharmacology"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibiotic Prophylaxis"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Bacteria"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Bacteroides fragilis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Biological Availability"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Disease Models, Animal"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Escherichia coli"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Fluoroquinolones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mice"
    },
    {
      "QualifierName": [
        "pharmacokinetics",
        "pharmacology"
      ],
      "DescriptorName": "Naphthyridines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Sprague-Dawley"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Rats, Wistar"
    },
    {
      "QualifierName": [
        "drug therapy",
        "microbiology",
        "prevention & control"
      ],
      "DescriptorName": "Surgical Wound Infection"
    }
  ]
}